eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | hartnup disease |
| Comorbidity | C0026769|multiple sclerosis |
| Sentences | 13 |
| PubMedID- 22587224 | The presence and severity of ccvsi in multiple sclerosis correlate with disease status but has no or very limited association with clinical disability. |
| PubMedID- 21631944 | In support of this is the fact that elevated soluble micb correlated with disease activity in patients with multiple sclerosis during relapses while soluble mica did not show any association with the disease; rather, the levels of this ligand were similar to healthy controls [52]. |
| PubMedID- 23807840 | Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis. |
| PubMedID- 23096035 | [side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the yaroslavl region]. |
| PubMedID- 25877850 | Natalizumab is licensed for relapsing remitting multiple sclerosis in patients with high disease activity despite treatment with interferon-beta and patients with rapidly evolving severe, multiple sclerosis. |
| PubMedID- 21846991 | Association of th1/th2-related chemokine receptors in peripheral t cells with disease activity in patients with multiple sclerosis and neuromyelitis optica. |
| PubMedID- 20090344 | Natalizumab reduces clinical and mri activity in multiple sclerosis patients with high disease activity: results from a multicenter study in switzerland. |
| PubMedID- 21304907 | Switching multiple sclerosis patients with breakthrough disease to second-line therapy. |
| PubMedID- 19660239 | Neuropsychiatric manifestations in multiple sclerosis: correlation of fatigue and depression with disease progression. |
| PubMedID- 21352517 | Management of breakthrough disease in patients with multiple sclerosis: when an increasing of interferon beta dose should be effective? |
| PubMedID- 23625177 | Intrathecal soluble hla-e correlates with disease activity in patients with multiple sclerosis and may cooperate with soluble hla-g in the resolution of neuroinflammation. |
| PubMedID- 24332164 | We found that mir-155 expression was highly correlated with disease severity in patients with multiple sclerosis and mice with experimental autoimmune encephalomyelitis (eae). |
| PubMedID- 25206559 | Cortical disease has emerged as a critical aspect of the pathogenesis of multiple sclerosis, being associated with disease progression and cognitive impairment in patients with early-stage multiple sclerosis. |
Page: 1